Abpro Holdings, Inc. Nasdaq Delisting Update

Event Description

Abpro Holdings, Inc., a biopharmaceutical company focused on developing new antibody treatments, is facing a major challenge: Nasdaq is delisting its shares. This means Abpro's common stock and warrants will no longer trade on Nasdaq and are expected to move to a less regulated market.

Nasdaq is taking this action because Abpro didn't meet the exchange's minimum stockholders' equity requirement, specifically Nasdaq Listing Rule 5550(b)(1). Even though Nasdaq had previously given Abpro an extension until February 16, 2026, to fix this, the company couldn't meet that deadline. This failure really highlights some serious financial struggles, likely due to ongoing losses and not having enough capital.

Event Date/Timeline

Abpro officially received notice of the delisting decision from the Nasdaq Hearings Panel on February 18, 2026.

Nasdaq plans to stop trading Abpro's shares (ABP) and warrants (ABPWW) when the market opens on February 23, 2026.

The company has 15 days from February 18, 2026, to appeal this decision to the Nasdaq Listing and Hearing Review Council. This follows an earlier decision by the Nasdaq Hearings Panel on November 10, 2025, which had set the original compliance deadline.

Impact Assessment

This Nasdaq delisting is a really tough blow for Abpro Holdings, Inc., and it has big implications for everyone involved:

For the Company:

• Loss of Prestige and Visibility: Getting kicked off Nasdaq, a major global exchange, can really hurt Abpro's reputation. It also makes it much harder for big institutional investors to even see the company, as many only invest in stocks listed on major exchanges.
• Operational Focus Shift: Management will have to spend a lot of time and resources trying to fix these financial problems and figure out how to get back on a major exchange or find other ways to get funding. This takes their focus away from developing new drugs.
• Difficulty Securing Partnerships: Losing a major exchange listing makes it tougher to find strategic partners for drug development or commercialization. Potential partners might see Abpro as a higher risk or worry about its ability to raise money.
• Hampered Drug Development: Because it will be harder to raise capital (which we'll talk more about in the Financial Impact section), funding for crucial drug development could be severely affected. This might delay clinical trials or even stop the company from bringing new therapies to patients.

For Investors:

• Reduced Liquidity and Increased Volatility: Trading will likely move to the OTC Pink Market, which is much less regulated and transparent. You'll probably find it much harder to buy or sell shares quickly, and prices could swing wildly. The difference between buying and selling prices (the spread) is also expected to get much wider.
• Limited Accessibility: Not all brokerage firms allow trading on the OTC Pink Market, which could make it even harder for you to buy or sell shares.
• Higher Risk: The OTC Pink Market comes with significantly higher risk because there's less oversight, less information readily available, and lower liquidity. This dramatically increases the risk of holding Abpro shares.
• Potential Price Decline: The stock price will likely take a big hit and experience high volatility as the market reacts to this news and the move to a less liquid market.

For Employees:

• This news can be unsettling, raising questions about the company's financial health and future, which may impact morale and job security.

Financial Impact

Abpro's delisting happened because it couldn't meet Nasdaq's minimum stockholders' equity requirement. This points to some serious underlying financial problems, including ongoing operational losses and not having enough capital.

While the 8-K filing didn't give us specific financial projections or put a number on the direct costs of the delisting process, moving to the OTC Pink Market will definitely have a big impact on the company's finances and its ability to get funding in the future. This will likely:

• Increase the cost of capital: Raising money through selling more stock or taking on debt will become more expensive and much harder because Abpro is no longer on a major public exchange and is seen as higher risk.
• Reduce access to institutional investors: Many big institutional investors are simply not allowed to invest in securities that aren't listed on a major exchange.
• Negatively affect valuation: Delisting usually leads to a significant drop in the company's total market value and its share price.
• Hamper drug development funding: It will be much harder to raise capital, which will severely impact the company's ability to fund critical research and development. This could lead to delays or even the cancellation of clinical trials.

The company didn't provide much detail about specific financial impacts like potential write-downs, direct delisting expenses, or a revised financial outlook in their filing.

Key Takeaways for Investors

Here's what you, as an investor, should really pay attention to:

• Immediate Impact: Brace yourself for a significant drop in the stock price and high volatility as the market reacts to this news.
• Trading Changes: Your shares will no longer trade on Nasdaq. If they move to the OTC Pink Market, it will be much harder to buy or sell quickly, and you might get a much less favorable price. Remember, not all brokers facilitate trading on the OTC Pink Market.
• Increased Risk: The OTC Pink Market carries significantly higher risk due to less oversight, less available information, and lower liquidity. This substantially increases the risk profile of holding Abpro shares.
• Re-evaluate Your Investment: This is a fundamental change in the company's public market status and clearly signals underlying financial challenges. Seriously reconsider if this stock still fits with your investment goals and how much risk you're comfortable with.
• Watch the Appeal: Keep an eye out for any news regarding Abpro's appeal to Nasdaq. While it's a long shot, a successful appeal would be a positive development.
• Long-Term Outlook: This event could severely hurt Abpro's ability to fund its operations and drug development in the long run, especially since the company hasn't shared a detailed strategic plan to address its financial challenges and get back into compliance.